A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

This trial is testing a drug called NADUNOLIMAB in combination with azacitidine (with or without venetoclax) for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) — two serious blood cancers. The goal is to find out if adding NADUNOLIMAB improves treatment responses in patients who either haven't yet tried standard options or haven't responded well to them. **You may be eligible if...** - You are 18 years of age or older - You have been diagnosed with intermediate, high, or very high risk MDS and have had no more than 2 prior treatments (Arm 1), OR - You have relapsed or refractory AML and are starting your 1st or 2nd salvage treatment, or your MDS progressed to AML (Arm 2) - You are in reasonable physical health (ECOG score 2 or less) - Your organ function is adequate **You may NOT be eligible if...** - You have active uncontrolled infections - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding - You have active brain involvement from your cancer - You have received certain prior treatments that disqualify you Talk to your doctor to see if this trial is right for you.